AI Article Synopsis
- The study evaluated outcomes in metastatic renal cell carcinoma (mRCC) patients treated with sunitinib, focusing on refining IMDC classification for better prognostic accuracy.
- A new cutoff point was established for categorizing patients, revealing three groups with varying prognostic factors and overall survival (OS) rates: 32.9 months for favorable-intermediate, 20.0 months for real-intermediate, and 8.9 months for poor prognosis.
- The findings were validated in an independent cohort, confirming these significant OS differences, indicating the need for further research to enhance treatment strategies.
Article Abstract
Background: The International mRCC (metastatic renal cell carcinoma) Database Consortium (IMDC) is the standard classification for mRCC. We aimed to evaluate the outcomes of a large cohort of patients with an intermediate or a poor prognosis treated with sunitinib using a different cutoff point for IMDC to improve the classification.
Patients And Methods: Patients with an intermediate or a poor prognosis according to the IMDC criteria and treated with sunitinib were included in the present study. A new cutoff point was used to categorize the patients. The new score was validated in an independent cohort of patients.
Results: A total of 457 patients were included in the present study. Significant differences in overall survival (OS) were highlighted regarding the number of prognostic factors. Three categories were identified according to the presence of 1 (ie, favorable-intermediate group), 2 (ie, real-intermediate group), and > 2 (ie, poor group) factors. The corresponding median OS periods were 32.9, 20.0, and 8.9 months, with significant differences among the groups. The validation cohort included 389 patients. The median OS period for the favorable-intermediate group, real-intermediate group, and poor group was 34.3, 19.4, and 9.0 months, respectively, with confirmed significant differences among the groups.
Conclusion: Our analysis revealed significant differences among patients with an intermediate prognosis using the IMDC prognostic factors. Further investigations to optimize the use of available and upcoming therapies are required.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.clgc.2018.04.007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!